| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Institute of Pharmacology, University of Genova School of Medicine; the Unit of Neuroscience, Advanced Biotechnology Center; and the Service of Pharmacology, National Institute for Cancer Research, Genova; the Department of Cellular and Molecular Biology and Pathology "L. Califano," University of Naples Federico II (M.T.B.), Naples; the Center of Endocrinology and Experimental Oncology, Consiglio Nazionale Delle Ricerche (S.S., MT.B.), Naples; and the Department of Clinical and Experimental Medicine, University of Reggio Calabria (A.F.), Catanzaro, Italy
Address all correspondence and requests for reprints to: Prof. Gennaro Schettini, Unit of Neuroscience, Advanced Biotechnology Center, National Institute for Cancer Research, Largo Rosanna Benzi 10, 16132 Genova, Italy. E-mail: schettini{at}sirio.cba.unige.it
The effects of the stable expression of E1A and/or middle T oncogenes
on the proliferative activity of PC Cl3 normal thyroid cells are
reported. The proliferation of PC Cl3 cells is mainly regulated by
insulin and TSH in a stimulatory way and by somatostatin in an
inhibitory fashion. The transformed cell lines, named PC Py and PC E1A
Py, show an autonomous pattern of proliferation. The blockade of
phosphotyrosine phosphatase activity with vanadate increased the
proliferation rate of PC Cl3 under basal and stimulated conditions and
completely prevented the inhibitory activity of somatostatin,
suggesting that in PC Cl3 cells, a tonic tyrosine phosphatase activity
regulates basal and stimulated proliferation, and that a
somatostatin-dependent increase in this activity may represent a
cytostatic signal. Conversely, in both PC Py and PC E1A Py, vanadate
did not modify basal and stimulated proliferation. We analyzed tyrosine
phosphatase activity in the different cell lines basally and under
conditions leading to the arrest of cell proliferation: confluence
(contact inhibition), growth factor deprivation (starvation), and
somatostatin treatment. Under basal conditions, tyrosine phosphatase
activity was significantly lower in PC Py and PC E1APy cell lines than
that in the normal cells. The inhibition of the proliferation induced
by contact inhibition or somatostatin treatment was accompanied by an
increase in tyrosine phosphatase activity only in PC Cl3 cells. The
reduction in tyrosine phosphatase activity in PC E1APy cells correlated
with a significant reduction in the expression of R-PTP
, a tyrosine
phosphatase cloned from PC Cl3 cells. Conversely, the expression of
another receptor-like PTP, PTPµ, was unchanged. Thus, PTP
may be a
candidate to mediate inhibitory signals (i.e. activation
of somatostatin receptors or cell to cell contact) on the proliferative
activity of PC Cl3 cells, and the reduction of its expression in the
transformed cell lines may lead to an alteration in the control of cell
proliferation.
This article has been cited by other articles:
![]() |
F. Barbieri, A. Pattarozzi, M. Gatti, C. Porcile, A. Bajetto, A. Ferrari, M. D. Culler, and T. Florio Somatostatin Receptors 1, 2, and 5 Cooperate in the Somatostatin Inhibition of C6 Glioma Cell Proliferation in Vitro via a Phosphotyrosine Phosphatase-{eta}-Dependent Inhibition of Extracellularly Regulated Kinase-1/2 Endocrinology, September 1, 2008; 149(9): 4736 - 4746. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Arena, A. Pattarozzi, A. Massa, J.-P. Esteve, R. Iuliano, A. Fusco, C. Susini, and T. Florio An Intracellular Multi-Effector Complex Mediates Somatostatin Receptor 1 Activation of Phospho-Tyrosine Phosphatase {eta} Mol. Endocrinol., January 1, 2007; 21(1): 229 - 246. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Massa, F. Barbieri, C. Aiello, S. Arena, A. Pattarozzi, P. Pirani, A. Corsaro, R. Iuliano, A. Fusco, G. Zona, et al. The Expression of the Phosphotyrosine Phosphatase DEP-1/PTP{eta} Dictates the Responsivity of Glioma Cells to Somatostatin Inhibition of Cell Proliferation J. Biol. Chem., July 9, 2004; 279(28): 29004 - 29012. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. L. Palka, M. Park, and N. K. Tonks Hepatocyte Growth Factor Receptor Tyrosine Kinase Met Is a Substrate of the Receptor Protein-tyrosine Phosphatase DEP-1 J. Biol. Chem., February 14, 2003; 278(8): 5728 - 5735. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Florio, S. Arena, S. Thellung, R. Iuliano, A. Corsaro, A. Massa, A. Pattarozzi, A. Bajetto, F. Trapasso, A. Fusco, et al. The Activation of the Phosphotyrosine Phosphatase {eta} (r-PTP{eta}) Is Responsible for the Somatostatin Inhibition of PC Cl3 Thyroid Cell Proliferation Mol. Endocrinol., October 1, 2001; 15(10): 1838 - 1852. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Hershman and E. S. Levitan RPTP{micro} and protein tyrosine phosphorylation regulate K+ channel mRNA expression in adult cardiac myocytes Am J Physiol Cell Physiol, February 1, 2000; 278(2): C397 - C403. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Florio, H. Yao, K. D. Carey, T. J. Dillon, and P. J. S. Stork Somatostatin Activation of Mitogen-Activated Protein Kinase via Somatostatin Receptor 1 (SSTR1) Mol. Endocrinol., January 1, 1999; 13(1): 24 - 37. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |